Recordati Rare Diseases Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Recordati Rare Diseases Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11332
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:16
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Recordati Rare Diseases Inc (RRD), a subsidiary of Recordati SpA is a biopharmaceutical company that discovers and develops orphan drugs and biologics. The company’s products comprise chemet, neoprofen, panhematin, desoxyn, mustargen, carbaglu, cosmegen, peganone and tranxene, among others. It offers its products in the forms of capsules, injections and tablets. RRD’s products are used in the treatment of rare diseases such as acute intermittent porphyria, patent ductus arteriosus, Wilms’ tumor, NAGS deficiency, nonseminomatous testicular cancer, and others. The company markets its products through its distributors located across the US, Canada and others. RRD is headquartered in Lebanon, New Jersey, the US.

Recordati Rare Diseases Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Recordati Rare Diseases Acquires North American Rights to Cystadane 10
Partnerships 11
Prasco Labs Enters into Distribution Agreement with Recordati Rare Diseases 11
Ony Enters Into Co-Promotion Agreement With Recordati Rare Diseases For NeoProfen 12
Recordati Rare Diseases Inc – Key Competitors 13
Recordati Rare Diseases Inc – Key Employees 14
Recordati Rare Diseases Inc – Locations And Subsidiaries 15
Head Office 15
Appendix 16
Methodology 16
About GlobalData 16
Contact Us 16
Disclaimer 16

List of Tables
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Key Facts 2
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Recordati Rare Diseases Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Recordati Rare Diseases Acquires North American Rights to Cystadane 10
Prasco Labs Enters into Distribution Agreement with Recordati Rare Diseases 11
Ony Enters Into Co-Promotion Agreement With Recordati Rare Diseases For NeoProfen 12
Recordati Rare Diseases Inc, Key Competitors 13
Recordati Rare Diseases Inc, Key Employees 14

List of Figures
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Recordati Rare Diseases Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bangkok Bank Public Co Ltd:企業の戦略・SWOT・財務情報
    Bangkok Bank Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Bangkok Bank Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Tenaska Energy, Inc.:企業の戦略・SWOT・財務情報
    Tenaska Energy, Inc. - Strategy, SWOT and Corporate Finance Report Summary Tenaska Energy, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Lixte Biotechnology Holdings Inc (LIXT):企業の財務・戦略的SWOT分析
    Lixte Biotechnology Holdings Inc (LIXT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Briscoe Group Limited (BGP):企業の財務・戦略的SWOT分析
    Briscoe Group Limited (BGP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Mahle GmbH:企業の戦略的SWOT分析
    Mahle GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Papa John’s International, Inc.:戦略・SWOT・企業財務分析
    Papa John's International, Inc. - Strategy, SWOT and Corporate Finance Report Summary Papa John's International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Pepsi-Cola Products Philippines Inc:戦略・SWOT・企業財務分析
    Pepsi-Cola Products Philippines Inc - Strategy, SWOT and Corporate Finance Report Summary Pepsi-Cola Products Philippines Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • OraSure Technologies Inc (OSUR):医療機器:M&Aディール及び事業提携情報
    Summary OraSure Technologies Inc (OraSure) is a manufacturer and distributor of oral fluid specimen collection devices, diagnostic products and other medical devices. Its product portfolio encompasses infectious disease tests for the detection of antibodies for the HIV and Hepatitis C virus; Ebola v …
  • WorleyParsons Limited:企業の戦略・SWOT・財務分析
    WorleyParsons Limited - Strategy, SWOT and Corporate Finance Report Summary WorleyParsons Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Rosseti (RSTI):電力:M&Aディール及び事業提携情報
    Summary Rosseti is an electricity grid company. It operates energy networks, and transmits and distributes electricity in Russia. Rosseti operates through a portfolio of affiliated and dependent companies including interregional and regional distribution grid companies. Through joint projects and ot …
  • R Pharm-製薬・医療分野:企業M&A・提携分析
    Summary R Pharm is a pharmaceutical company that offers drug development and manufacturing. The company offers finished dosage forms, active pharmaceutical ingredients (api) and biotechnological substances. It provides products in therapeutic areas of oncology, hematology, immune diseases, antibioti …
  • Simcere Pharmaceutical Group-製薬・医療分野:企業M&A・提携分析
    Summary Simcere Pharmaceutical Group (Simcere) is a drug discovery company that manufactures and supplies branded generic and prescription pharmaceutical products. The company offers products in therapeutic areas including anti-tumor, central nervous, anti-infection, cardiovascular, skeletal muscle, …
  • VentriPoint Inc:製品パイプライン分析
    Summary VentriPoint Inc (VentriPoint), a subsidiary of VentriPoint Diagnostics Ltd is a medical device company that manufactures and distributes medical devices for the cardiovascular market. The company’s product VMS is a heart visualization system which is used to evaluate right heart function. It …
  • Williams-Sonoma, Inc.:戦略・SWOT・企業財務分析
    Williams-Sonoma, Inc. - Strategy, SWOT and Corporate Finance Report Summary Williams-Sonoma, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Alteogen Inc (196170):製薬・医療:M&Aディール及び事業提携情報
    Summary Alteogen Inc (Alteogen) is a biotech company that develops proprietary antibody-drug conjugate and antibody biosimilars. The company’s pipeline products include ALT-P1, ALT-Q2, ALT-P7, ALT-Q5, ALT-L9 and ALT-L2. Its products are used for long-acting human growth hormone, long-acting factor V …
  • Ferndale Pharma Group Inc-製薬・医療分野:企業M&A・提携分析
    Summary Ferndale Pharma Group Inc (Ferndale Pharma), formerly Ferndale Laboratories Inc is a manufacturer and distributor of pharmaceutical products. The company provides surgical instruments, medical supplies, skin care products, topical therapeutic products, prescription, over the counter products …
  • Vistin Pharma AS (VISTIN)-製薬・医療分野:企業M&A・提携分析
    Summary Vistin Pharma AS (Vistin), a subsidiary of Vistin Pharma ASA is a healthcare company that produces and supplies solid dosage forms and active pharmaceutical ingredients. The company’s products include metformin, an API for the treatment of diabetes II; opioids, an analgesics and antitussive; …
  • Zai Lab Ltd (ZLAB):製薬・医療:M&Aディール及び事業提携情報
    Summary Zai Lab Ltd (Zai Lab) is a biopharmaceutical company that discovers, develops and manufactures transformative medicines for cancer, autoimmune and infectious diseases. The company’s pipeline products include ZL-2306, ZL-2401, FPA144, EXT2514SUL, ZL-2301, ZL-3101, ZL-2302 and ZL-1101. It deve …
  • Day & Zimmermann Group, Inc.:戦略・SWOT・企業財務分析
    Day & Zimmermann Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Day & Zimmermann Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • BerGenBio ASA (BGBIO)-製薬・医療分野:企業M&A・提携分析
    Summary BerGenBio ASA (BerGenBio) is a developer of drugs for aggressive and drug resistant cancers. The company develops epithelial-mesenchymal transition inhibitors for acquired cancer drug-resistance and metastasis. Its BGB324 finds application in the treatment of drug resistant chronic myeloid l …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆